Literature DB >> 26685181

The Impact of Hypoglycemia on the Cardiovascular System: Physiology and Pathophysiology.

Shi-Wei Yang1, Kyoung-Ha Park2, Yu-Jie Zhou3.   

Abstract

Intensive glycemic control may increase cardiovascular (CV) risk and mortality due to hypoglycemia. The pathophysiology of glucose counter-regulation in patients with type 1 or type 2 diabetes for over 15 years is characterized by impairment of the defense mechanisms against hypoglycemia. Hypoglycemia causes pronounced physiological and pathophysiological effects on the CV system as consequences of autonomic system activation and counter regulatory hormones release. These effects provoke a series of hemodynamic changes that include an increase in heart rate and peripheral systolic blood pressure, a decrease in central blood pressure, reduced peripheral arterial resistance, and increased myocardial contractility and cardiac output. Cardiac electrophysiological changes including flattening or inversion of T waves, QT prolongation, and ST segment depression were observed in both insulin-induced and spontaneous hypoglycemia. Sympathoadrenal activation is the main cause of these changes through mechanisms that involve, but are not limited to, catecholamine-mediated hypokalemia. Hypoglycemia is also involved in platelet activation. There is growing concern about the long-term effects of hypoglycemia, especially as related to inflammation and atherogenesis.
© The Author(s) 2015.

Entities:  

Keywords:  cardiovascular risk; diabetes; hypoglycemia; physiological and pathophysiological effects

Mesh:

Substances:

Year:  2015        PMID: 26685181     DOI: 10.1177/0003319715623400

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  7 in total

1.  Effects and mechanisms of glucose-insulin-potassium on post-procedural myocardial injury after percutaneous coronary intervention.

Authors:  Yi-Dan Hao; Peng Hao; Zheng Wang; Ying-Xin Zhao; Zhi-Ming Zhou; Yu-Yang Liu; De-An Jia; Hong-Ya Han; Bin Hu; Hua Shen; Fei Gao; Guo-Zhong Pan; Zhen-Feng Guo; Shi-Wei Yang; Yu-Jie Zhou
Journal:  J Geriatr Cardiol       Date:  2020-09-28       Impact factor: 3.327

2.  A Retrospective Cohort Study of Patients with Type 2 Diabetes in China: Associations of Hypoglycemia with Health Care Resource Utilization and Associated Costs.

Authors:  Yingping Yi; Yawei Li; Anran Hou; Yanqiu Ge; Yuan Xu; Gang Xiong; Xinlei Yang; Stephanie Ann Acevedo; Lizheng Shi; Hua Xu
Journal:  Diabetes Ther       Date:  2018-04-05       Impact factor: 2.945

3.  Hypoglycemia does not affect the progression of preclinical atherosclerosis in subjects with type 2 diabetes.

Authors:  Concetta Irace; Antonio Cutruzzolà; Delia Francesca Carbotti; Simona Mastroianni; Michela Cavallo; Agostino Gnasso
Journal:  PLoS One       Date:  2019-03-05       Impact factor: 3.240

4.  High triglyceride-glucose index is associated with poor prognosis in patients with acute ST-elevation myocardial infarction after percutaneous coronary intervention.

Authors:  Erfei Luo; Dong Wang; Gaoliang Yan; Yong Qiao; Bo Liu; Jiantong Hou; Chengchun Tang
Journal:  Cardiovasc Diabetol       Date:  2019-11-13       Impact factor: 9.951

5.  Patient-Generated Health Data Integration and Advanced Analytics for Diabetes Management: The AID-GM Platform.

Authors:  Elisa Salvi; Pietro Bosoni; Valentina Tibollo; Lisanne Kruijver; Valeria Calcaterra; Lucia Sacchi; Riccardo Bellazzi; Cristiana Larizza
Journal:  Sensors (Basel)       Date:  2019-12-24       Impact factor: 3.576

Review 6.  Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes.

Authors:  Dario Giugliano; Miriam Longo; Lorenzo Scappaticcio; Paola Caruso; Katherine Esposito
Journal:  Cardiovasc Diabetol       Date:  2021-01-11       Impact factor: 9.951

7.  Atherosclerosis Risk Factors in Patients with Reactive Hypoglycemia.

Authors:  Małgorzata Landowska; Agata Żebrowska; Konrad Fajer; Patrycja Adamek; Aleksandra Kruk; Bernadetta Kałuża; Edward Franek
Journal:  Diabetes Metab Syndr Obes       Date:  2022-10-14       Impact factor: 3.249

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.